血脂水平、他汀类药物治疗与脑出血风险
Blood lipid levels, statin therapy and the risk of intracerebral hemorrhage.
作者信息
Ma Yingxu, Li Zhaokai, Chen Liang, Li Xiangping
机构信息
Department of Cardiology, The Second Xiangya Hospital, Central South University, #139 Middle Renmin Road, Changsha, Hunan, 410011, PR China.
The Eight-Year Clinical Medicine of Grade 2012, Xiangya School of Medicine, Central South University, Changsha, Hunan, 410013, PR China.
出版信息
Lipids Health Dis. 2016 Mar 1;15:43. doi: 10.1186/s12944-016-0213-8.
Dyslipidemia has been proven to play an important role in the occurrence and development of the ischemic stroke and lipid-lowering therapy could significantly decrease the risk of the ischemic stroke. However, the association between lipid levels, lipid-lowering therapy and the risk of intracerebral hemorrhage (ICH) is not clear. Studies have shown that low serum levels of total cholesterol might be associated with increasing risk of ICH, whereas the SPARCL study, a large prospective, randomized, placebo-controlled trial, demonstrated an increased risk of hemorrhagic stroke during high-dose statin therapy among the patients with previous stroke. The relationship between lipid-lowering therapy and ICH has become a hot topic in the recent years. We searched PubMed for articles published in English to review the existing evidence on the association of lipid levels, statin therapy and risk of ICH as well as the underlying mechanisms in order to provide practical recommendations for clinical decision-making and a foundation for further researches.
血脂异常已被证明在缺血性卒中的发生和发展中起重要作用，降脂治疗可显著降低缺血性卒中的风险。然而，血脂水平、降脂治疗与脑出血（ICH）风险之间的关联尚不清楚。研究表明，血清总胆固醇水平低可能与ICH风险增加有关，而SPARCL研究（一项大型前瞻性、随机、安慰剂对照试验）表明，既往有卒中的患者在大剂量他汀类药物治疗期间出血性卒中风险增加。近年来，降脂治疗与ICH之间的关系已成为一个热门话题。我们在PubMed上搜索了以英文发表的文章，以回顾关于血脂水平、他汀类药物治疗与ICH风险之间关联的现有证据以及潜在机制，以便为临床决策提供实用建议，并为进一步研究奠定基础。
Zotero 插件